Accounting Value per Share: MiNK Therapeutics, Inc (INKT)

Official company branding of MiNK Therapeutics (INKT)

MiNK Therapeutics, Inc. (INKT) revenues rely on the future sale of iNKT-therapy drugs for cancer treatment. The book value of equity per share on the GURU.Markets system summary chart reflects the asset's dynamics, where the value is maintained at -2.73. The company is actively developing treatments for solid tumors, yet faces fierce competition for leadership within the immuno-oncology niche.

INKT MiNK Net Asset Value per Share (07/04/2022 - 10/30/2026)

INKT (minktherapeutics.com): analytical breakdowns and indicator data

- current quotes and average value forecast:
Price Chart MiNK|INKT - Analyst Consensus Forecast
- company stock exchange capitalization indicators:
Market Valuation MiNK Therapeutics, Inc.|INKT - Aggregate Business Value
- balance sheet net asset value indicators:
Net Assets per Single Share MiNK Therapeutics|INKT - Total Stockholders' Equity|Market Value to Book Value Ratio minktherapeutics.com|INKT - Total Business Assets
- business debt structure and liquidity details:
Total Debt to Capital MiNK Therapeutics, Inc.|INKT - Long-Term Debt to Equity Ratio|Short-Term Debt to Equity MiNK Therapeutics|INKT - Company Cumulative Debt|Debt to Book Capitalization Ratio MiNK Therapeutics, Inc.|INKT - Company Long-Term Debt|Company Short-Term Debt MiNK Therapeutics|Quick Ratio minktherapeutics.com
- earnings and multiples data:
INKT - Annual Net Income
Basic company analysis:INKT - MiNK
Manufactured products of MiNK Therapeutics

Book value per share reflects the portion of net assets, defined as the difference between the issuer's total equity and liabilities. By analyzing the reference book value per share, investors assess the intrinsic value of the business, which is particularly critical for MiNK Therapeutics, Inc. (INKT), whose capitalization relies on authoritative developments in iNKT cells and innovative oncology treatment methods.

Competitor analysis for MiNK Therapeutics, Inc.

IBRX - Net Assets per Single Share|IMCR - Book Value per Share|JANX (Janux Therapeutics) - Accounting Value per Share|RCUS: Book Price of a Share|Net Assets per Single Share Zymeworks|Net Asset Value per Share Tango Therapeutics Inc TNGX|Net Assets per Single Share Iovance (IOVA)|Immatics Biotechnologies - Equity per Share|Book Value per Share XNCR (Xencor, Inc.)|CMPX - Accounting Value per Share|REPL - Net Assets per Single Share|Net Asset Value per Share Lyell|Innate Pharma, S.A. (IPHA) - Net Assets per Single Share|PYXS (Pyxis Oncology) - Net Assets per Single Share|Net Assets per Single Share Compugen Ltd|Net Asset Value per Share iobiotech.com IOBT|Book Value per Share STRO|werewolftx.com (HOWL) - Book Value of One Share|Immix Biopharma - Accounting Value per Share|ALX Oncology Holdings Inc. (ALXO) - Net Asset Value per Share|CUE: Accounting Value per Share|Accounting Value of a Share PDSB (PDS Biotechnology)|SONN: Book Value per Share|MAIA - Net Assets per Share|Net Assets per Single Share Liminatus Pharma Corp|Accounting Value per Share Lava Tx (LVTX)|Net Assets per Single Share NextCure, Inc. (NXTC)|Accounting Value per Share leaptx.com LPTX|Intensity Therapeutics, Inc. - Accounting Value per Share|Book Value per Share Sensei Biotherapeutics Inc SNSE|TOVX - Net Assets per Single Share|GRTS (Gritstone bio, Inc.) - Equity per Share|Kineta, Inc. (KA) - Net Assets per Single Share|Net Asset Value per Share neximmune.com (NEXI)|Accounting Value per Share TSBX|VCNX - Book Value of One Share|Accounting Value per Share HARP (Harpoon Tx)